GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regen BioPharma Inc (OTCPK:RGBP) » Definitions » Debt-to-Revenue

Regen BioPharma (Regen BioPharma) Debt-to-Revenue : 2.94 (As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Regen BioPharma Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Regen BioPharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.55 Mil. Regen BioPharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.14 Mil. Regen BioPharma's annualized Revenue for the quarter that ended in Mar. 2024 was $0.24 Mil. Regen BioPharma's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 was 2.94.


Regen BioPharma Debt-to-Revenue Historical Data

The historical data trend for Regen BioPharma's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regen BioPharma Debt-to-Revenue Chart

Regen BioPharma Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 19.52 23.68 20.95 5.40 3.19

Regen BioPharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 2.59 3.21 3.03 2.94

Competitive Comparison of Regen BioPharma's Debt-to-Revenue

For the Biotechnology subindustry, Regen BioPharma's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Regen BioPharma's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regen BioPharma's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Regen BioPharma's Debt-to-Revenue falls into.



Regen BioPharma Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Regen BioPharma's Debt-to-Revenue for the fiscal year that ended in Sep. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0.607 + 0.15) / 0.237
=3.19

Regen BioPharma's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0.55 + 0.144) / 0.236
=2.94

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Mar. 2024) Revenue data.


Regen BioPharma Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Regen BioPharma's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Regen BioPharma (Regen BioPharma) Business Description

Traded in Other Exchanges
Address
4700 Spring Street, Suite 304, La Mesa, CA, USA, 91942
Regen BioPharma Inc is a US-based biotechnology company. It focuses on the development of regenerative medical applications in the stem cell space. The company's principal products and services include HemaXellarate I, HemaXellerate II, dCell Vax, NR2F6, Tcellvax, identification of Small Molecules, and others. HemaXellarate I and HemaXellerate II is a cellular therapy designed to heal damaged bone marrow. dCell Vax is a therapy whereby dendritic cells of the cancer patient are harvested from the body. Tcellvax is an autologous cellular product comprised of NR2F6 gene-silenced peripheral blood mononuclear cells.